Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Endometrial Cancer

Endometrial Cancer

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Endometrial Cancer

118 trials tracked for Endometrial Cancer: 9 in phase 3 or 4 and 5 with published results. The most-cited published study has 369 citations.

118Trials tracked
9Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 9 Phase 2 82 Phase 1 7 Other / NA 20
  1. Phase 3 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Completed · 369 cited
  2. Phase 3 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed · 232 cited
  3. Phase 3 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Completed · 143 cited
  4. Phase 3 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) Completed · 66 cited
  5. Phase 3 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed · 10 cited
  6. Phase 3 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study Completed
Show 44 more trials
  1. Phase 3 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed
  2. Phase 3 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed
  3. Phase 3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed
  4. Phase 2 A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone Completed
  5. Phase 2 SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma Completed
  6. Phase 2 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma Completed
  7. Phase 2 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  8. Phase 2 A Trial for Patients With Advanced/Recurrent Endometrial Cancer Completed
  9. Phase 2 A Study of Patients Receiving High-Dose Rate Brachytherapy Completed
  10. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  11. Phase 2 Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  12. Phase 2 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer Completed
  13. Phase 2 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer Completed
  14. Phase 2 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Completed
  15. Phase 2 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed
  16. Phase 2 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Completed
  17. Phase 2 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Completed
  18. Phase 2 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer Completed
  19. Phase 2 A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer Completed
  20. Phase 2 A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer Completed
  21. Phase 2 Survivorship Promotion In Reducing IGF-1 Trial Completed
  22. Phase 2 Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers Completed
  23. Phase 2 ZW25 in Women With Endometrial Cancers Completed
  24. Phase 2 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed
  25. Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed
  26. Phase 2 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed
  27. Phase 2 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed
  28. Phase 2 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  29. Phase 2 Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression Completed
  30. Phase 2 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  31. Phase 2 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed
  32. Phase 2 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer Completed
  33. Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Completed
  34. Phase 2 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed
  35. Phase 2 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Completed
  36. Phase 2 A Study of Nivolumab in Selected Uterine Cancer Patients Completed
  37. Phase 2 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Completed
  38. Phase 2 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer Completed
  39. Phase 2 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Completed
  40. Phase 2 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed
  41. Phase 2 Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  42. Phase 2 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed
  43. Phase 2 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed
  44. Phase 2 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Completed

Showing the 50 most-cited and recently-updated of 118 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Combined pelvic and para-aortic lymphadenectomy improves overall survival compared to no lymphadenectomy in endometrial cancer
Oncology Meta-analysis
Combined pelvic and para-aortic lymphadenectomy improves overall survival compared to no lymphadenectomy in endometrial cancer Combined lymphadenectomy may improve survival for endometrial cancer patients
This meta-analysis of 25,432 patients found that combined pelvic and para-aortic lymphadenectomy (PPaLND) is associated with significant imp…
A large review of over 25,000 cases suggests that a more extensive surgical removal of lymph nodes can improve survival in some endometrial …
Frontiers Jun 11, 2026
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer
Oncology Meta-analysis
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer Mapping the Research Landscape of Immune Therapy for Endometrial Cancer
This systematic review uses a bibliometric analysis to map the landscape of immune checkpoint inhibitor research in endometrial cancer. The …
A large-scale analysis maps out how researchers worldwide are studying immune checkpoint inhibitors to treat endometrial cancer.
Frontiers Jun 8, 2026
Tumor budding associates with adverse clinicopathological features and reduced overall survival in cervical and endometrial cancer
Oncology Meta-analysis
Tumor budding associates with adverse clinicopathological features and reduced overall survival in cervical and endometrial cancer Tumor Budding Linked to Worse Outcomes in Cervical and Endometrial Cancer
This Bayesian meta-analysis of 18 observational cohort studies involving 3320 patients with cervical or endometrial cancer evaluated the pro…
Small clusters of cells breaking away from cervical and endometrial tumors signal more aggressive disease and worse survival outcomes.
Apr 9, 2026
Molecular-profile guided adjuvant treatment shows cost-effectiveness versus standard VBT in HIR-EC
OB/GYN & Women's Health RCT
Molecular-profile guided adjuvant treatment shows cost-effectiveness versus standard VBT in HIR-EC Can a new cancer test save money without sacrificing quality of life?
A phase 3 RCT of 564 women with early-stage high-intermediate risk endometrial cancer found molecular-integrated-profile guided adjuvant tre…
A new cancer test guided by molecular profiles cut healthcare costs for endometrial cancer patients without lowering their quality of life o…
Apr 5, 2026